ROCKVILLE, Md.--(November 13, 2019)--NeoImmuneTech, Inc., a clinical-stage T-cell focused biopharmaceutical company dedicated to expanding the immuno-oncology frontier, today announced the appointment of distinguished research and development thought leaders to a newly formed scientific advisory board (“SAB”). The SAB will help guide NeoImmuneTech in its efforts to advance a pipeline of novel immunotherapeutics to treat cancer and infectious diseases.
“The formation of our Scientific Advisory Board is an important step for NeoImmuneTech in our ongoing quest to expand the frontier of immuno-oncology,” said Se Hwan Yang, Ph.D., Chief Executive Officer of NeoImmuneTech. “These highly respected leaders will bring rich scientific insights in addition to an external academic and industry perspective to our continuing development of Hyleukin-7 and our growing pipeline of immunotherapies.”
NeoImmuneTech’s Scientific Advisory Board members are:
Hyleukin-7™, the only clinical-stage long-acting human IL-7, is uniquely positioned to address unmet medical needs in immuno-oncology. IL-7 is a fundamental cytokine for T-cell development and for sustaining immune response to chronic antigens (as in cancer). Hyleukin-7's favorable PK/PD and safety profiles make it an ideal combination partner for immunotherapy standard of care (SOC) such as Checkpoint Inhibitor and CAR-T therapies. Hyleukin-7 is being studied in multiple clinical trials in solid tumors, and being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T-cell focused biopharmaceutical company dedicated to expanding the immuno-oncology frontier with Hyleukin-7 and beyond. NIT is partnering with industry and academic leaders to investigate Hyleukin-7 in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.